NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
25 trialsNCT07415525 2026-02-17
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
Zhejiang University
Phase 2 Not yet recruiting
NCT07354919 2026-01-21
AxeCan
HealthPartners Institute
Phase 2 Not yet recruiting
NCT07126158 2026-01-05
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT06177522 2025-11-18
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Jinling Hospital, China
Phase 2 Not yet recruiting
NCT07208539 2025-10-06
ZSPAC-14
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07173387 2025-09-15
RAD-NALIRIFOX
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT07160283 2025-09-08
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT04901741 2025-06-27
OPTIMUS
TME Pharma AG
Phase 2 Not yet recruiting
NCT06991491 2025-05-28
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
West China Hospital
Phase 2 Not yet recruiting
NCT06938282 2025-04-25
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06916975 2025-04-08
CSPAC-48
Fudan University
Phase 2 Not yet recruiting
NCT05562297 2025-01-22
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06700603 2024-11-22
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06621095 2024-10-01
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
RenJi Hospital
Phase 2 Not yet recruiting
NCT06531291 2024-07-31
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
Phase 2 Not yet recruiting
NCT06233864 2024-04-17
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06361030 2024-04-11
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06234072 2024-02-02
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Shenzhen University General Hospital
Phase 2 Not yet recruiting
NCT06210360 2024-01-18
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
Changhai Hospital
Phase 2 Not yet recruiting
NCT04889742 2023-12-26
HETERERO
Charite University, Berlin, Germany
Phase 2 Not yet recruiting
NCT06166589 2023-12-12
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT05810792 2023-11-22
PANCEP-1
Sahlgrenska University Hospital
Phase 2 Not yet recruiting
NCT05637567 2023-11-13
ASAP
German Cancer Research Center
Phase 2 Not yet recruiting
NCT06080854 2023-10-12
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting